Medical

Elective knee
replacement surgery

The pandemic led to a spate of postponed and cancelled surgeries that temporarily depressed the global market for knee implants. Although the market is returning to pre-Covid levels, the expected surge from clearing the significant backlogs has yet to arrive.

Last updated: March 16, 2022
LINGERING EFFECTS FROM THE COVID-19 PANDEMIC

Over the past 20 years, an ageing global population, more sedentary and less active lifestyles, technological advances and decreasing production costs have all made orthopaedic implants for knee replacement surgery a real growth industry.

But, like so many other global industries and services over the past couple of years, the market for knee implants has been hit hard by the Covid-19 pandemic.

Ali Madani is the founder and head of Avicenne Medical, one of the world’s leading consultancies on the market for orthopaedic medical devices. He has some stark findings to share.

 

Knee implant

The global market for knee implants fell by 21% between 2019 and 2020. Although there wasn’t the strong level of growth enjoyed between 2000 and 2010, the market had had a healthy compound annual growth rate of 3.9% between 2015 and 2019, so it’s clear that the pandemic had a dramatic braking effect”

So, how has Covid-19 affected knee implant surgery? Is it just a case of clearing a backlog of postponements to rebound? Is the market otherwise strong?

DELAYS, CANCELLATIONS AND LOST HEALTH INSURANCE

Lockdowns around the globe meant hospitals needed to prioritise urgent Covid cases over elective surgery. Even when prospective patients’ surgeries could be rescheduled, fear of infection made many reluctant to go to the hospital. Both factors contributed to the sharp fall in the knee implants market in 2020.

And, in the case of the United States, which at more than 50% market share has by far the biggest customer base in the world for this type of surgery, there is an added complication, as Ali Madani explains:

“In the US, most employees get medical cover through their job. So, losing your job in the US means losing your health insurance, and consequently cancelling any operations, until you find a new job or pay out of your own pocket – and American healthcare is very expensive.”

According to World Economic Outlook 2020, the US unemployment rate ballooned during the first wave of the pandemic, from 7.1 million people in mid-March 2020 to a staggering 36.5 million people just two months later. That meant a huge fall in health insurance numbers and, thus, operations, too.

An aging global population is one reason for the growth of knee replacement surgery.

The global market for knee implants fell by 21% between 2019 and 2020.

“Some surgeries have been completely lost and will never be recovered,” says market expert Ali Madani.

The US has more than half the global market in knee surgeries, but the pandemic economy hit this hard.

Leading market consultant Ali Madani says the recovery of the knee implant sector is still uneven.

CHALLENGES – NOT JUST CLEARING BACKLOGS

The US economy is now recovering. By July 2021, unemployment had fallen to 8.1 million people, nearly back to pre-Covid levels. Could the country’s status as a bellwether market signal a return to better times?

And in addition to this, the World Economic Outlook 2021 projects that the real GDP of advanced economies (the strongest markets for orthopaedic implant surgeries) will grow by 5.6% this year, compared with the 4.6% drop of 2020.

But it’s not just a case of clearing operation backlogs (complicated enough in itself). Other issues make the resumption of ‘normal’ demand difficult to predict.

Some surgeries were cancelled, not postponed. Patients’ reluctance to reschedule, having other health issues, and changes to health insurance packages when people change job are some of the factors in this vanished business. “Some surgeries have been completely lost and will never be recovered,” says Ali Madani.

There are other pressures. A reimbursement trend results in downward price pressure, and this is the main limiter of the orthopaedic market.

“Price erosion of mature products in orthopaedics has been a constant over the past 20 years. We do not expect a major shift, but some countries will suffer a more significant price decrease than others,” says Ali Madani.

Regulation is a further challenge. The introduction of the European Union’s Medical Device Regulation in May 2021, following the Medical Device Directive in 2019, has been pushing OEMs in Europe to reduce their implant product ranges and drastically increase their regulatory budgets to meet stringent certification requirements. That sucks away money that could otherwise be spent on research and product development.

“Regulatory issues (and the associated costs) are becoming heavier and resulting in a longer time to market for new product launches and a more limited range of products,” adds Ali Madani.

OPPORTUNITIES AND UNCERTAINTIES AHEAD

Nevertheless, 2020 could be seen as an outlier amid an overall trend towards continuing growth. Avicenne Medical forecasts that the orthopaedic market overall will grow by 3.8% between 2019 and 2025 and puts the corresponding growth in the knee segment at 3.2%.

“There are several drivers at play here,” says Ali Madani. “They include a high growth in the volume of surgeries in emerging countries as their economies strengthen and with it their healthcare sectors. Globally, the upward demographic and rising economic purchasing power will continue to have a positive effect on the sector.”

Furthermore, while the markets in developed countries have long since matured from the boom time of 2000 to 2010, there are new growth areas. New entrants are challenging the major players in the market with disruptive innovations such as smart implants and cheaper 3D-printed components, leading to the majors buying up rivals.

Nonetheless, Ali Madani says that these opportunities are matched by some continuing uncertainties, especially for those big, established players.

“The major companies in the sector, which accounted for 65% of the market in 2020, have not all recovered the 2019 level by the first half of 2021. We believe that by the end of 2021, the majors will not reach the 2019 level and the two years of lost growth.”

 

 

So, after all the uncertainties and challenges of the past couple of years, the knee implants segment is still unsettled, though there are signs of underlying growth. It’s just a question of what kind of market will emerge when the pandemic eventually comes to an end.

(for further information, please contact Ali Madani )

Do you want to explore more Seco solutions in the medical segment? Click here